COMMUNIQUÉS West-GlobeNewswire

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
16/09/2024
Please see enclosed pdf. Attachment 16092024_trading_in_shares_KV
Impact BioMedical Inc. Announces Pricing of Initial Public Offering
16/09/2024
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness today announced the pricing of its initial [...]
Capsa Healthcare’s New Interactive Website Assists Healthcare Leaders in Technology Decision Making
16/09/2024
COLUMBUS, Ohio, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Capsa Healthcare , a pioneer in health IT, medication management, and pharmacy automation, today announced the launch of a new interactive website designed to help [...]
Trading by management and close relations of management
16/09/2024
Please read the full announcement in PDF Attachment 2024_37_Trading_By_Management
L’association RYBREVANT®▼ (amivantamab) plus chimiothérapie démontre un taux de réponse globale de 49 pour cent dans le cancer colorectal métastatique
16/09/2024
La durée médiane de la réponse atteint 7,4 mois avec le traitement combiné chez les patients atteints d’une forme agressive de la maladie 1 De nouveaux résultats démontrent l’efficacité de l’amivantamab au-delà du [...]
ARC Fertility Sponsors Purchaser Business Group on Health 2024 Maternal Health and Birth Equity Summit
16/09/2024
CUPERTINO, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ARC Fertility (ARC), a highly experienced national provider of innovative fertility and family-forming benefits for employers and their employees, is pleased to [...]
RYBREVANT®▼ (amivantamab) associé à une chimiothérapie montre une tendance de survie globale positive par rapport à la chimiothérapie chez les patients atteints d'un cancer du poumon muté par EGFR préalablement traité
16/09/2024
Les résultats suite à la progression ont mis en évidence une amélioration significative et durable pour l'amivantamab plus chimiothérapie par rapport à la chimiothérapie seule 1 BEERSE, BELGIQUE, 16 sept. 2024 (GLOBE [...]
WellRithms Featured for Fourth Consecutive Year on Portland Business Journal List of Fastest-Growing Private Companies
16/09/2024
PORTLAND, Ore., Sept. 16, 2024 (GLOBE NEWSWIRE) -- WellRithms , the industry leading payment integrity firm, announces the Company’s fourth consecutive year of recognition from the Portland Business Journal as one of [...]
Thought Leadership & Innovation Foundation Announces Gala to Initiate Development of Patient Portal for Age-Related Macular Degeneration
16/09/2024
Howard Fine, MD Delivers Keynote MCLEAN, Va., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Thought Leadership & Innovation Foundation (TLI) , a not-for-profit organization that works at the nexus of science, technology and [...]
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
16/09/2024
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group ") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is [...]
Novo Nordisk A/S - share repurchase programme
16/09/2024
Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 [...]
Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy
16/09/2024
Vivtex to apply its GI-ORIS™ technology to optimize oral bioavailability of EQ302, Equillium’s novel IL-15/IL-21 bi-specific peptide therapy Equillium targeting initiation of Phase 1 study investigating EQ302 in 2H 2025 [...]
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
16/09/2024
GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]
London Man Grateful to Doctors Who Treated Rare Flesh-Eating Disease, Pledges $25,000
16/09/2024
LONDON, Ontario, Sept. 16, 2024 (GLOBE NEWSWIRE) -- While on vacation in Napa Valley last year, Colleen DeJager’s world imploded when she received a startling call from back home—her husband Rick was admitted to London [...]
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
16/09/2024
Expands available market to include over 200 children’s hospitals in the United States LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid [...]
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
16/09/2024
Strengthens Rare Disease segment as largest driver of future growth , adding approximately $105 million in 2024 revenue on a pro forma basis Adds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth [...]
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
16/09/2024
Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx ® (cabozantinib) versus placebo in advanced pancreatic and extra-pancreatic [...]
Les résultats finaux de l’essai de Phase III CABINET corroborent les bénéfices en termes d’efficacité de Cabometyx® dans les tumeurs neuroendocrines avancées
16/09/2024
Les données ont démontré une réduction significative, tant sur le plan statistique que sur le plan clinique, du risque de progression de la maladie ou de décès avec Cabometyx ® (cabozantinib) par rapport au placebo dans [...]
NeuroStar® Releases Software Upgrades to Elevate Patient Care
16/09/2024
Upgrades improve communication, streamline data management, and strengthen security MALVERN, Pa., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, [...]

Pages